Other less commonly selected criteria included: patient preference (27.8%), the potential side effects of insulin as compared with those of other antihyperglycemic medications (25%), patient weight (22.2%), the patient work schedule and lifestyle factors (16%), availability of nurses, diabetes educators and others to implement and follow the insulin treatment (16.7%), and the cost of insulin (9.3%). This evidence concerns the gene INS and diabetes mellitus.